title: [Standards, Options and Recommendations for the management of stage I or II primary bronchial cancers treated exclusively with radiotherapy].
abstract: BACKGROUND
  The 'Standards, Options and Recommendations' (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French cancer centres and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.
  
  
  OBJECTIVE
  To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the management of stage I and II non small cell lung carcinoma treated by radiotherapy alone.
  
  
  METHODS
  Data were identified by searching Medline and personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to independent reviewers, and to the medical committees of the 20 French cancer centres.
  
  
  RESULTS
  The main recommendations for the management of stage I and II non small cell lung carcinoma treated by radiotherapy alone are: 1) The curative external irradiation with a continual course is an alternative to surgery only in the case of medically inoperable tumors or because the patient refuses surgery; 2) The external irradiation of the primary tumor only without the mediastinum could be proposed in peripheral stage IA. In proximal stage IA and IB, external irradiation should be carried out only as part of prospective randomised controlled trials comparing a localised irradiation of the primary tumor with a large irradiation of the mediastinum and the primary tumor. The treated volume must include the macroscopic tumoral volume with or without the microscopic tumoral volume and with a security margin from 1.5 to 2 cm; 3) There is a benefit to delivering a total dose in the primary tumor higher than 60 Gy in so far as the proposed irradiation, taking into account the respiratory function, does not increase the likelihood of severe adverse events due to radiation; and 4) The change in fractionation, the radiochemotherapy combination, the endobronchial brachytherapy with high dose rate alone or with external irradiation could be proposed only as part of prospective controlled trials for tumors classified as stage IB or II.
authors.affiliation: Hôpital Tenon, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Touboul
authors.forename: J L
authors.initials: JL
authors.lastname: Lagrange
authors.forename: S
authors.initials: S
authors.lastname: Theobald
authors.forename: P
authors.initials: P
authors.lastname: Astoul
authors.forename: P
authors.initials: P
authors.lastname: Baldeyrou
authors.forename: E
authors.initials: E
authors.lastname: Bardet
authors.forename: B
authors.initials: B
authors.lastname: Bazelly
authors.forename: J
authors.initials: J
authors.lastname: Bréchot
authors.forename: J L
authors.initials: JL
authors.lastname: Breton
authors.forename: J Y
authors.initials: JY
authors.lastname: Douillard
authors.forename: M
authors.initials: M
authors.lastname: Grivaux
authors.forename: P
authors.initials: P
authors.lastname: Jacoulet
authors.forename: A
authors.initials: A
authors.lastname: Khalil
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: E
authors.initials: E
authors.lastname: Lemarie
authors.forename: Y
authors.initials: Y
authors.lastname: Martinet
authors.forename: G
authors.initials: G
authors.lastname: Massard
authors.forename: B
authors.initials: B
authors.lastname: Milleron
authors.forename: D
authors.initials: D
authors.lastname: Moro-Sibilot
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: J L
authors.initials: JL
authors.lastname: Pujol
authors.forename: A E
authors.initials: AE
authors.lastname: Quoix
authors.forename: E
authors.initials: E
authors.lastname: Ranfaing
authors.forename: A
authors.initials: A
authors.lastname: Rivière
authors.forename: H
authors.initials: H
authors.lastname: Sancho-Garnier
authors.forename: P J
authors.initials: PJ
authors.lastname: Souquet
authors.forename: D
authors.initials: D
authors.lastname: Spaeth
authors.forename: A
authors.initials: A
authors.lastname: Stoebner-Delbarre
authors.forename: L
authors.initials: L
authors.lastname: Thiberville
authors.forename: F
authors.initials: F
authors.lastname: Vaylet
authors.forename: J M
authors.initials: JM
authors.lastname: Vergnon
authors.forename: V
authors.initials: V
authors.lastname: Westeel
authors.forename: A
authors.initials: A
authors.lastname: Depierre
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001918:Brachytherapy / Q000379:methods / Q000592:standards; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy*; D002985:Clinical Protocols / Q000592:standards; D003131:Combined Modality Therapy; D005602:France / Q000453:epidemiology; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods / Q000592:standards; D011879:Radiotherapy Dosage; D012107:Research Design / Q000592:standards; D016896:Treatment Outcome
vernacular_title: Standards, Options et Recommandations pour la prise en charge des patients atteints d'un cancer bronchique primitif de stade I ou II traités par irradiation exclusive.